Results 141 to 150 of about 345,615 (256)

Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era. [PDF]

Clin Infect Dis
Churchyard GJ, Swindells S, Gupta A, Shah NS, Hughes M, Kim S, Fox GJ, Harrington M, Chaisson RE, Hesseling AC.   +9 more
europepmc   +1 more source

Enhanced strategies for cuproptosis‐like death in bacterial infection treatment

BMEMat, EarlyView.
This review summarizes and examines the molecular mechanisms underlying cuproptosis‐like death. Furthermore, multi‐strategy efficacy enhancement and potential enhancement approaches are analyzed. Abstract Copper, a classical antibacterial metal, has long been of interest and widely used in medical and public health applications.
Wenqi Wang, Bolong Xu, Ruiyuan Zhu, Hengshuo Gui, Tian Xia, Shaokai Liu, Huiyu Liu, Xianwen Wang   +7 more
wiley   +1 more source

Extensive Lymphadenopathy in an HIV-Negative Patient With Multidrug-Resistant Tuberculosis. [PDF]

Respirol Case Rep
Araya T, Kita T, Iwasaki K, Higashi T, Hara R, Takato H.   +5 more
europepmc   +1 more source

From Food Waste to Valorized Nanomaterials: Sustainable Green Synthesis and Biomedical Applications

ChemFoodChem, EarlyView.
Food waste‐derived biomolecules act as natural reducing and stabilizing agents for the green synthesis of functional NPs with applications in antimicrobial systems, food packaging, biomedical technologies, and environmental remediation. ABSTRACT Food waste is a global issue, with billions of tons discarded and unutilized annually, causing economic ...
Siddhraj Rajput, Gautam Priyadarshi, Santosh Kumar Sahu, Bhakti Patel, Avni Thakker, Sherzodbek Tashbaev, Gulomov Gafurjon Shavkatbek Ugli, Dipak Kumar Sahoo, Ashish Patel   +8 more
wiley   +1 more source

Sociodemographic and Clinical Correlates of Multidrug-Resistant Uropathogens in Hospitalized Children. [PDF]

Infect Drug Resist
Muhsen K, Haleem S, Mansour B, Shapira M, Pitashny M, Masarwa M, Omar M, Na'aminh W, Kassem E.   +8 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Antimicrobial Effect of Postbiotics on Multidrug-Resistant Escherichia coli. [PDF]

Foods
Sezer Ç, Bilge N, Büyük GD, Ayyıldız Akın M.   +3 more
europepmc   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel. [PDF]

Sci Rep
Wang J, Hornicek FJ, Shi H, Feng W, Duan Z.   +4 more
europepmc   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source